A new study by UCLA Health has discovered what researchers say is the first drug to fully reproduce the effects of physical ...

Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. On average, equities research analysts forecast that Nevro will post -2.44 earnings per share for the current year.

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

Kohberger had a judge enter a not-guilty plea to the first-degree murder charges on his behalf after remaining silent at his May 2023 arraignment. Although his trial was set to begin Oct. 2 ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...

March is Traumatic Brain Injury Awareness Month, a condition that has led to permanent disability in more than 5 million individuals in the United States. Healio spoke with Gregory Hawryluk, MD, PhD, ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted ... lifted in 2022 after an investigation ...

A long-planned “quick-build” bike lane on Oak Street suffered a slowdown, but now it is back on the table. Pending final approval, the San Francisco Municipal Transportation Authority is ...

Deshaun Watson and girlfriend Jilly Anais announce their engagement amidst his uncertain NFL career and injury setbacks. Watson, recently plagued by injuries, faces a challenging future with the ...

Former accused turned state witness, Laurentia Lombaard will enter her third day in the witness box in the Joshlin Smith disappearance trial in Saldanha, Western Cape on Monday morning.

Symptomatic cerebral cavernous malformation is a rare disease, and affected individuals are at risk of strokes due to intracerebral haemorrhage or new non-haemorrhagic neurological deficits.